The Controversial Approval of Aduhelm and Its Implications

This chapter examines the contentious approval process of the Alzheimer's drug Aduhelm, which was launched without proven efficacy in clinical trials. It critiques the FDA's regulatory lapses and the potential consequences for drug pricing and patient access in the U.S. healthcare system.